(Total Views: 450)
Posted On: 06/04/2021 10:46:15 PM
Post# of 36541
Re: OrlandoJohn #29916
It’s my fault you’re missing a part of the story. Someone came on here attacking Doc, Joe and Generex. I deleted his posts so context is lost.
Josh is the Barron’s writer that Doc wrote to as noted in Doc’s prior posts. However, with Gnbt trading well under $1, typically they then are a publicly traded company that won’t be written about. Very often $1 is the lowest share price amount allowed to write a positive story about.
I hope we start to see Generex and NuGenerex promote themselves as well. Many small successful biotechs I follow still hit up investor events even if virtually. And hopefully that peer review mentioned last Fall comes to publication. All of that can help.
Josh is the Barron’s writer that Doc wrote to as noted in Doc’s prior posts. However, with Gnbt trading well under $1, typically they then are a publicly traded company that won’t be written about. Very often $1 is the lowest share price amount allowed to write a positive story about.
I hope we start to see Generex and NuGenerex promote themselves as well. Many small successful biotechs I follow still hit up investor events even if virtually. And hopefully that peer review mentioned last Fall comes to publication. All of that can help.
(6)
(0)Scroll down for more posts ▼
